The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

PR NewswireMar 31 20:49 ET

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TipRanksMar 30 09:15 ET · Ratings

Advanced Cell-based Therapy Booming the Success for Healthcare Sector

PR NewswireMar 24 10:00 ET

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Iovance BiotherapeuticsMar 20 00:00 ET

Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Yahoo FinanceMar 13 22:41 ET

Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BenzingaMar 12 08:02 ET